Phase 2 N=50 ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Alzheimer's Disease
Primary: Treatment Emergent Adverse Events (TEAEs) — 21; 23 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.
Attention Deficit Disorder With Hyperactivity
Primary: RAAPP: Rating of Aggression Against People and/or Property Scale — 4.3; 3.2; 2.0 units on a scale — p=<0.05
Phase 2 N=57 Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Cachexia
Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 — 2.0; 0.65 Percentage Change of TMV
Phase 2 N=79 Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
HIV Infections
Primary: The Antiretroviral Activity of Etravirine 400 mg Given Once Daily, With Fixed-dose Truvada Once Daily, Among Treatment-naïve HIV-1 Infected Adults as Measured by the…
Phase 2 N=70 Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma · Recurrent Ovarian Carcinoma · Stage IV Ovarian Cancer
Primary: Median Time to Progression — 7.2 months
Phase 2 N=110 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Phase 2 N=68 Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
Acute Pain
Primary: Responders on Pain Intensity(PI) and Pain Relief (PR) Composite Endpoint — 1; 1 responders
Phase 2 N=64 Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer · Stage IV Ovarian Epithelial Cancer
Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants
Phase 2 N=14 Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
Urea Cycle Disorders
Primary: Venous Ammonia Levels at the Peak and Mean TNUAC Time-normalized Area Under the Curve) — 79.1; 56.3; 38.4; 26.5 μmol/L
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 2 N=11 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
Orthostatic Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg
Phase 2 N=139 Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
Fragile X Syndrome
Primary: Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the Aberrant Behavior Checklist-Community Edition (ABC-CFX) Total Score in Stratum I Patients…
Phase 2 N=57 Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Rectal Adenocarcinoma · Stage II Rectal Cancer AJCC v7 · Stage III Rectal Cancer AJCC v7
Primary: Pathologic Complete Response Rate — 17 percentage of participants
Phase 2 N=16 N-acetylcysteine and NMDA Antagonist Interactions
Cognitive Dysfunction
Primary: Target P300 — 2.5; 3.2; 5.2; 3.4 microvolts
Phase 2 N=55 Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival Rate — 10.3 months — p=0.10